Are some diseases associated with a higher risk of venture capital losses?

Are some diseases associated with a higher risk of venture capital losses? 

Before summer we posted a study correlating venture capital losses in drug development with the magnitude of funding of clinical trials. We have used two approaches to find losses: 1) Companies that Pitchbook registers with a “distressed deal”, 2) Companies with M&A transaction multiples of lower than 1x; focusing on European drug development companies founded after year 2000 and with more than EUR 2M raised.  
 
Below we have studied the correlation between losses and choice of disease area.  

In the left panel we have ranked the indications according to number of losses. 

Some biotech investors, Sunstone included, are reluctant to invest in infectious diseases. The therapy payment models are not attractive and the established industry seems disinclined to buy infectious disease focused companies. The data below confirms that the field is subject to many losses and that some investors have learned the relevance of commercial viability the hard way!  
 
Oncology is the second disease category with a high loss rate, but data from our previous M&A analysis suggests that oncology ranks high in M&A frequency. In the right panel we have normalized losses relative to successes (EUR >50M M&A). Infectious diseases remain risky, while the many losses in oncology seem balanced by a higher likelihood of success – at least over the past 20 years. Cardiovascular diseases also have a high Loss to Success ratio, but numbers are low (11 losses and 1 success) and we hesitate to conclude anything.  
 
We have also analysed the average raise for the three disease areas with the highest number of losses (>20): oncology – EUR 21M per company; infectious diseases – EUR 19M per company; CNS – EUR 16M per company. Surprisingly it appears less costly to fail in CNS. Maybe CNS focused clinical trials are more definitive – whereas oncology trials are more explorative and facilitate a second try – and eventually a more costly failure?  
 
In general, we find that the diseases that seem more exposed to losses match Sunstone’s experiences – and according to the data above, an experience we apparently share with some of our industry colleagues 🙂
 
Let us know what you think!
#sunstonelifescience #lifescience #venturecapital

What do you think?
Let us know in our feed on LinkedIn:

5 latest press releases

Ascelia Pharma Successfully Meets Primary Endpoint with Strong Headline Results in Orviglance Phase 3 Study

Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that liver imaging drug candidate, Orviglance®, significantly improved visualization of focal liver lesions, successfully...

Fund IV company Cardior Pharmaceuticals acquired by Novo Nordisk

Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart. The company’s therapeutic approach targets distinctive non-coding RNAs as a platform for addressing root causes of...

MinervaX Raises EUR 54M in Upsized Financing to Advance the Development of its Maternal Vaccine Against Group B Streptococcus

MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), has today announced the completion of a EUR 54 million upsized financing. The financing includes investment from new investors EQT...

Teitur Trophics Raises EUR 28M in Series A Financing to advance the development and treatment for neurodegenerative diseases

Teitur Trophics (“Teitur”), a biotech company dedicated to developing new treatments for patients suffering from neurodegenerative diseases, today announces the completion of a €28M Series A financing. The financing was co-led by Sunstone Life Science Ventures and...

Galecto Completes Enrollment in Phase 1b_2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

BOSTON, March 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced it has completed enrollment in Parts 2 and 3 of its ongoing 3-part...

5 latest articles

The VC summer dream – the Fund Returner

Sunstone has over the past years continuously highlighted observations and learnings from successes in European biotech. The learnings have consolidated, tuned and verified our current investment strategy. Sunstone is today primarily an early stage (pre-clinical/phase...

Are we making a tangible difference?

We are a Life Science Venture Capital with a passion for investing in drug development, both because it is extremely exciting but also because we contribute to moving new therapies closer to patients with severe, untreated diseases – we matter! – we make a tangible...

Sunstone has supported and funded companies that have been the originator of 20 life-changing products

Since the inception in 2007, Sunstone Life Science Ventures (Sunstone) has co-created, supported and funded life science companies that have been the originator of 20 life-changing products approved for the treatment or diagnosis of patients with cardiovascular,...

Biotech startups in Scandinavia have 460 MEUR at hand – but burn is up – and runway the shortest in 3 years

As the market continues to fluctuate and geopolitical issues continue to impact the economy, it's important to take a closer look at the state of pre-commercial life science companies. At Sunstone, we assisted companies in our portfolio with listings and refinancing,...

Unmet medical needs in cardiovascular sub-populations – an opportunity for VCs?

Unmet medical needs in cardiovascular sub-populations – an opportunity for VCs?  For the past 5 months we have had the pleasure of having Philip Brainin as intern at Sunstone Life Science Ventures. Apart from bringing valuable insights to our daily activities, he has...

Why do VC’s not cut losses in time?

Why do VC’s not cut losses in time?  A clinical trial is a very expensive experiment for testing a hypothesis, while hoping for a positive outcome. However, if well designed, a negative outcome could increase the potential for a positive outcome in a subsequent trial....